# Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment

> **NCT02496182** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Grupo Medifarma, S. A. de C. V.** · enrollment: 60 (estimated)

## Conditions studied

- Alveolitis Extrinsic Allergic
- Pulmonary Fibrosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Pirfenidone
- **DRUG:** Pirfenidone

## Key facts

- **NCT ID:** NCT02496182
- **Lead sponsor:** Grupo Medifarma, S. A. de C. V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-07
- **Primary completion:** 2016-01
- **Final completion:** 2017-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2015-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02496182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02496182, "Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02496182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*